Cellbion Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,382,316 | Humanized anti-EMAP II antibody and use thereof In force · USPTO record | In force | USPTO record | |
| US 9,012,604 | Triazanonane Derivatives or Pharmaceutically Acceptable Salt Thereof for Enhanced FLUORINE-18 Labeling In force · High confidence | In force | High confidence | |
| US 9,925,284 | Nanoparticle Coated with Ligand Introduced with Long Hydrophobic Chain and Method for Preparing Same In force · High confidence | In force | High confidence | |
| US 10,159,756 | Complex of Mannosyl Serum Albumin, Method of Preparing the Same, Optical Imaging Probe and Kit Comprising the Same In force · High confidence | In force | High confidence | |
| US 11,027,029 | Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 no status recorded
Showing 1 to 2 of 2, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/274,007 | Composition for Treating Sarcopenia or Osteoporosis Through Mechanism Promoting Formation of Muscle Fibers or Inhibiting Osteoclastogenesis, Comprising Cyclo-L-Phenylalanyl-L-Proline Dipeptides | Dec 29, 2021 | Pending |
| 13/516,460 | Nov 29, 2010 | No status recorded |